Advertisement

Topics

Latest "Alnara Pharmaceuticals" News Stories

01:38 EDT 21st July 2018 | BioPortfolio

Here are the most relevant search results for "Alnara Pharmaceuticals" found in our extensive news archives from over 250 global news sources.

More Information about Alnara Pharmaceuticals on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Alnara Pharmaceuticals for you to read. Along with our medical data and news we also list Alnara Pharmaceuticals Clinical Trials, which are updated daily. BioPortfolio also has a large database of Alnara Pharmaceuticals Companies for you to search.

Showing "Alnara Pharmaceuticals" News Articles 1–25 of 7,500+

Friday 20th July 2018

Week Ahead In Pharmaceuticals - 14 Stocks To Watch (LCI, INSY, TBPH...)

As another week comes to a close, let's take a look back at some of the stories that made headlines in the pharma space, and look ahead to what's in store in the coming week.


Global Food Grade Phosphoric Acid Market Segmented by Food grade Type, Application, and Geography 2018 2023 [Report Updated: 08022018] Prices from USD $1923

The food grade phosphoric acid market is expected to grow at a CAGR of 7.2% over the forecast period 2018 2023. The European and North American markets are expected to generate demand since recovering from the economy crisis.Growing demand for preservative food Sodium tripolyphosphate has applications in various enduser industries, such as food beverages, pharmaceuticals, agriculture and cosmeti...

Israel Ampoules Packaging Market Segmented By Material Glass, Plastic, Applications Pharmaceuticals, Personal Care, Industrial Growth, Trends, And Forecasts 2018 2023 [Report Updated: 01032018] Prices from USD $3250

The Israel ampoules packaging market is expected to register a CAGR of about 6.72% during 20182023 the forecast period. The pharmaceutical sector of the country has evolved significantly over the last few decade, emerging as one of the biggest exporters of pharmaceutical products across the globe. Currently, the country is the fourthbiggest exporter of pharmaceutical products to the United States....


Agios Pharma’s Drug for Rare Blood Cancer Wins Speedy FDA Nod

An Agios Pharmaceuticals drug developed to treat a rare form of leukemia has received FDA approval ahead of schedule. This marks the second time in the past year that the company has won the regulatory nod for a treatment for the disease, but this is the first approved drug that’s wholly owned by the Cambridge, […]

FDA approves Agios Pharmaceuticals’ Tibsovo for acute myeloid leukemia

The approval is the latest of several drugs approved for the disease, a form of blood cancer, sin

FDA approves Agios Pharmaceuticals leukemia drug

Agios Pharmaceuticals Inc said on Friday its oral drug to treat a type of leukemia was approved by the U.S. health regulator.

Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis

Corbus Pharmaceuticals (NASDAQ:CRBP) has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its lenabasum drug for the treatment of dermatomyositis (DM). As quoted in the press release: The FDA Orphan Drug Designation program provides a special status to drugs and biologics intended to treat, diagnose or prevent … Continued The post

FDA Grants Approval of Agios’ Pharmaceuticals’ TIBSOVO®

Agios Pharmaceuticals (NASDAQ:AGIO) has announced that TIBSOVO was granted approval from the US Food and Drug Administration (FDA) for treatment of adult patients with relapsed or refractory acute myeloid leukemia. As quoted in the press release: TIBSOVO®, an oral, targeted inhibitor of the IDH1 enzyme, is the first and only FDA-approved therapy for patients with … Continued The post FDA Gr...

Positive Phase 3 Data of Jazz’s Vyxeos in Patients with Acute Myeloid Leukemia Published in Journal of Clinical Oncology

DUBLIN, July 19, 2018 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that data from the pivotal Phase 3 study of Vyxeos® (daunorubicin and cytarabine) liposome for injection compared to standard of care cytarabine and daunorubicin (7+3) were published online in the Journal of Clinical Oncology. The study evaluated the efficacy and safety of Vyxeos compared to 7...

FDA Approves New Indications for Ferring’s Human Growth Hormone Zomacton

PARSIPPANY, N.J.–(BUSINESS WIRE)–Ferring Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ZOMACTON (somatropin) for injection in four additional pediatric indications: Idiopathic short stature (ISS) Short stature associated with Turner syndrome Short stature born small for gestational age (SGA) with no catch-up growth by 2 to 4 years Sh...

Agios Pharmaceuticals leukemia drug gets U.S. approval

Agios Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration approved its treatment for a type of leukemia, the first targeted drug for patients with a specific genetic mutation.

FDA OKs Ferring's Zomacton In Four Additional Pediatric Indications

NewsZomacton was previously approved to treat growth failure in pediatric patients due to inadequate secretion of endogenous growth hormone (GH) and replacement of endogenous GH in adults with GH deficiency.

Mylan and Lupin make deal for etanercept biosimilar

Indian generics manufacturer Lupin Pharmaceuticals (Lupin) and US-based drugmaker Mylan announced on 28 June 2018 that they had made a deal to commercialize an etanercept biosimilar.

Aquinox: Erste NBC-Empfehlung mit +40% in drei Wochen

Schon in den ersten Wochen zeigt sich der weltweit einmalige Wert des hochexklusiven No Brainer Clubs: Mit Aquinox Pharmaceuticals (WKN: A1XDJL) gewinnt die erste NBC-Empfehlung innerhalb von drei ...

FDA grants Breakthrough Device Designation for Roche's Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer's disease

F. Hoffmann-La Roche Ltd / FDA grants Breakthrough Device Designation for Roche's Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer's disease . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Basel, 20 July 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) ann...

20182023 UK Industrial Refrigeration Equipments Market Report Status and Outlook [Report Updated: 15032018] Prices from USD $3360

In 2017, the Industrial Refrigeration Equipments market size was xx million USD in UK, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In UK market, the top players include Ingersoll Rand Johnson Controls Daikin United Technologies Corporation Danfoss GEA Group Emerson Mayekawa BITZER Lennox International Yantai Moon Evapco Sha...

Global Contraceptive Drugs and Devices Market Segmented by Contraceptive Method, by Mode of Delivery, by Device, by Gender and Geography Growth, Trends and Forecasts 2018 2023 [Report Updated: 08022018] Prices from USD $4250

The Global Contraceptive Drugs and Devices Market was valued at USD 21.1 billion in 2017 and is projected to grow at a CAGR of 7.5% during the forecast period 2018 2023. China being the world's most populated country has around 1.36 billion population and has one of the highest rates of contraceptives use. Unintended pregnancies growing at a faster paceNot using of the contraceptives or the inco...

Thursday 19th July 2018

Global Food Grade Glycerin Market Growth, Trends and Forecasts 2018 2023 [Report Updated: 01032018] Prices from USD $4250

The global food grade glycerin market size was estimated to be USD 3.1 billion in 2017 and is anticipated to grow at a CAGR of 6.2% from 2017 to 2023 forecast period. Food grade glycerin has high applications in various consumer products due to it's functionally and nutritive benefits. In the food and beverage industry it has applications such as food preservatives, sweeteners and also as a humect...

Agios Pharmaceuticals Scores FDA Approval For Tibsovo, Second AML Drug Win in Less Than a Year

Shares of Agios Pharmaceuticals jumped this morning after the company said the FDA approved its oral leukemia treatment Tibsovo (ivosidenib). It’s the second approval for the company in less than a year.

Crinetics Pharmaceuticals Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, July 20, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the closing of its initial public offering of 6,900,000 shares of common stock, which includes the exercise i...

20182023 United States Industrial Refrigeration Equipment Market Report Status and Outlook [Report Updated: 15062018] Prices from USD $3360

In 2017, the Industrial Refrigeration Equipment market size was xx million USD in United States, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In United States market, the top players include Ingersoll Rand Johnson Controls Daikin United Technologies Corporation Danfoss GEA Group Emerson Mayekawa BITZER Lennox International Yantai ...

Journal of Clinical Oncology publishes pivotal Phase 3 data for Jazz Pharmaceuticals' Vyxeos (daunorubicin and cytarabine) Liposome for Injection

DUBLIN, July 19, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that data from the pivotal Phase 3 study of Vyxeos (daunorubicin and cytarabine) liposome for injectio...

ACADIA Pharmaceuticals Announces Appointment of Austin D. Kim as Executive Vice President, General Counsel and Secretary

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Austin D. Kim has joined ACADIA as Executive Vice President, General Counsel and Secretary. He will report to Steve Da...

Novel Protein Inhibitors Could Enhance Immunotherapy Response in Patients with Cancer

ArticleStudies to date have shown encouraging data for these drugs as potential combination therapies in indications such as metastatic pancreatic cancer, advanced bladder cancer and triple negative bladder cancer. Drug Discovery and Development spoke with Peter D. Suzdak, PhD, CEO of Rexahn Pharmaceuticals, whose company is on the forefront of some of these efforts, about the motivations and hope...

IRW-News: Aequus Pharmaceuticals: Aequus kündigt die Erweiterung der Marktchancen für sein Pflaster mit langfristiger Wirkung gegen Übelkeit an

IRW-PRESS: Aequus Pharmaceuticals: Aequus kündigt die Erweiterung der Marktchancen für sein Pflaster mit langfristiger Wirkung gegen Übelkeit an Aequus kündigt die Erweiterung der Marktchancen für...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks